<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01554202</url>
  </required_header>
  <id_info>
    <org_study_id>2007-A00414-49</org_study_id>
    <nct_id>NCT01554202</nct_id>
  </id_info>
  <brief_title>Multi-modal Neuroimaging in Alzheimer's Disease</brief_title>
  <acronym>IMAP</acronym>
  <official_title>Study of the Predictive Markers and the Pathophysiological Mechanisms of Alzheimer's Disease: Transverse and Longitudinal Approach in Anatomical and Functional Multimodal Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to estimations, Alzheimer's disease affects approximately 860,000 people aged of
      more than 65 years in France. This disease is characterized by disorders of cognitive
      functions, including memory, associated with structural and functional modifications of the
      brain. These changes are evolving within the pathology progression and can be evaluated with
      neuropsychological tests (to assess capabilities such as language, orientation, etc.) and
      also with brain imaging (e.g. MRI). Alzheimer's disease is still poorly understood,
      nevertheless currently available treatments can slow its development if the disease is
      diagnosed early enough.

      Thus, the objective is to identify markers for early diagnosis of Alzheimer's disease, to
      better describe the evolution of this disease.

      The three main objectives of this project are

        -  to identify, compare and combine predictive markers of Alzheimer's disease

        -  to make a significant contribution to the understanding of the pathophysiological
           mechanisms of Alzheimer's disease

        -  to study the ability of different neuroimaging techniques to follow the evolution of
           this pathology.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2008</start_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of volume change of whole brain, hippocampus and other structural MRI measures</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Decline as measured by: Cognitive Tests, Activities of Daily Living, and CDR Sum of Boxes</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rates of change on each specified biochemical biomarker</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rates of change of glucose metabolism (FDG-PET)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Extent of amyloid deposition as measured by 18F-AV45</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Group differences for each imaging and biomarker measurement</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>APOE genotype</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">295</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Young controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Middle age controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elderly controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autosomal dominant forms of early-onset Alzheimer disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjectif Cognitive Impariment patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Cognitive Impairment patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alzheimer Disease patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non degenerative amnsesic syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Frontotemporal lobe dementia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>assessment of memory</intervention_name>
    <arm_group_label>Young controls</arm_group_label>
    <arm_group_label>Middle age controls</arm_group_label>
    <arm_group_label>Elderly controls</arm_group_label>
    <arm_group_label>Autosomal dominant forms of early-onset Alzheimer disease</arm_group_label>
    <arm_group_label>Subjectif Cognitive Impariment patients</arm_group_label>
    <arm_group_label>Mild Cognitive Impairment patients</arm_group_label>
    <arm_group_label>Alzheimer Disease patients</arm_group_label>
    <arm_group_label>Non degenerative amnsesic syndrome</arm_group_label>
    <arm_group_label>Frontotemporal lobe dementia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>circulating tPA dosage</intervention_name>
    <arm_group_label>Young controls</arm_group_label>
    <arm_group_label>Middle age controls</arm_group_label>
    <arm_group_label>Elderly controls</arm_group_label>
    <arm_group_label>Autosomal dominant forms of early-onset Alzheimer disease</arm_group_label>
    <arm_group_label>Subjectif Cognitive Impariment patients</arm_group_label>
    <arm_group_label>Mild Cognitive Impairment patients</arm_group_label>
    <arm_group_label>Alzheimer Disease patients</arm_group_label>
    <arm_group_label>Non degenerative amnsesic syndrome</arm_group_label>
    <arm_group_label>Frontotemporal lobe dementia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>ApoE4</intervention_name>
    <arm_group_label>Young controls</arm_group_label>
    <arm_group_label>Middle age controls</arm_group_label>
    <arm_group_label>Elderly controls</arm_group_label>
    <arm_group_label>Autosomal dominant forms of early-onset Alzheimer disease</arm_group_label>
    <arm_group_label>Subjectif Cognitive Impariment patients</arm_group_label>
    <arm_group_label>Mild Cognitive Impairment patients</arm_group_label>
    <arm_group_label>Alzheimer Disease patients</arm_group_label>
    <arm_group_label>Non degenerative amnsesic syndrome</arm_group_label>
    <arm_group_label>Frontotemporal lobe dementia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Brain imaging examination MRI and PET examinations</intervention_name>
    <arm_group_label>Young controls</arm_group_label>
    <arm_group_label>Middle age controls</arm_group_label>
    <arm_group_label>Elderly controls</arm_group_label>
    <arm_group_label>Autosomal dominant forms of early-onset Alzheimer disease</arm_group_label>
    <arm_group_label>Subjectif Cognitive Impariment patients</arm_group_label>
    <arm_group_label>Mild Cognitive Impairment patients</arm_group_label>
    <arm_group_label>Alzheimer Disease patients</arm_group_label>
    <arm_group_label>Non degenerative amnsesic syndrome</arm_group_label>
    <arm_group_label>Frontotemporal lobe dementia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Education level &gt; 7 years

          -  Native language: French

          -  Medical, neurological, neuropsychological and neuroradiological depth in accordance
             with the criteria for inclusion and exclusion-specific population, that is to say:

               -  Healthy young controls: between 18 and 40 years old; normal performances compared
                  to the age and the educational level for all tests of the diagnostic battery (±
                  1.5 SD).

               -  Healthy Middle-aged controls: between 40 and 60 years old; without memory
                  complaints, normal performances compared to the age and the educational level for
                  all tests of the diagnostic battery (± 1.5 SD).

               -  Healthy Elderly controls: over 60 years old, living at home, without memory
                  complaints, normal performances compared to the age and the educational level for
                  all tests of the diagnostic battery (± 1.5 SD).

               -  MCI patients: over 60 years old, presenting the current criteria for amnestic MCI
                  including: i) memory complaint, ii) deficits of the episodic memory (lower
                  performance of at least 1.5 SD from the norm for age and cultural level for one
                  or more scores of episodic memory and iii) normal performances compared to the
                  age and the educational level of all other cognitive functions as memory,
                  including tests to assess cognitive abilities.

               -  Alzheimer's patients: presenting the standard criteria of NINCDS-ADRDA probable
                  Alzheimer's disease, including abnormal global cognitive function and deficits in
                  at least two cognitive domains identified by the diagnostic battery and a mild to
                  moderate Alzheimer's disease (MMSE ≥ 15).

        Exclusion Criteria:

          -  The sudden onset of cognitive impairments (as opposed to their slow and gradual
             installation in Alzheimer's disease)

          -  A chronic neurological, psychiatric, endocrine, hepatic or infectious complaint

          -  A history of major disease (an uncontrolled diabetes, a lung, heart, metabolic,
             hematologic, endocrine disease or a severe cancer);

          -  A medication that may interfere with memory or metabolic measures

          -  A alcohol or drugs abuse

          -  claustrophobia, metallic object in the body

          -  A predominantly left-hand (score below 50% in Edinburgh Inventory).

          -  Protected adults, and persons not affiliated with a social security system will not
             participate in this study.

          -  The inclusion of a participant in another biomedical research protocol (during the
             study or within 12 months before inclusion)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent de La Sayette, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Caen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Chételat G. [Neuroimaging Alzheimer's disease: early diagnosis, monitoring, and mechanism understanding]. Med Sci (Paris). 2011 Feb;27(2):193-8. doi: 10.1051/medsci/2011272193. Epub 2011 Mar 8. French.</citation>
    <PMID>21382329</PMID>
  </reference>
  <reference>
    <citation>Mevel K, Grassiot B, Chételat G, Defer G, Desgranges B, Eustache F. [The default mode network: cognitive role and pathological disturbances]. Rev Neurol (Paris). 2010 Nov;166(11):859-72. doi: 10.1016/j.neurol.2010.01.008. Epub 2010 Mar 11. Review. French.</citation>
    <PMID>20226489</PMID>
  </reference>
  <results_reference>
    <citation>La Joie R, Fouquet M, Mézenge F, Landeau B, Villain N, Mevel K, Pélerin A, Eustache F, Desgranges B, Chételat G. Differential effect of age on hippocampal subfields assessed using a new high-resolution 3T MR sequence. Neuroimage. 2010 Nov 1;53(2):506-14. doi: 10.1016/j.neuroimage.2010.06.024. Epub 2010 Jun 16.</citation>
    <PMID>20600996</PMID>
  </results_reference>
  <results_reference>
    <citation>Villain N, Landeau B, Groussard M, Mevel K, Fouquet M, Dayan J, Eustache F, Desgranges B, Chételat G. A simple way to improve anatomical mapping of functional brain imaging. J Neuroimaging. 2010 Oct;20(4):324-33. doi: 10.1111/j.1552-6569.2010.00470.x.</citation>
    <PMID>20331499</PMID>
  </results_reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2012</study_first_submitted>
  <study_first_submitted_qc>March 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2012</study_first_posted>
  <last_update_submitted>March 5, 2013</last_update_submitted>
  <last_update_submitted_qc>March 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>MCI</keyword>
  <keyword>genetic</keyword>
  <keyword>AV45-PET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

